IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting. Oct. 04, 2024 9:00 AM ET IO Biotech, Inc. (IOBT) ...

DELRAY BEACH, Fla., April 30, 2025--PanGIA Biotech, a company advancing urine-based, AI-driven diagnostics for early cancer detection, today announced that an abstract co-authored by researchers ...

CHICAGO, May 15, 2025--MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting ...

MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics MAIA seeks to advance two new THIO-derived telomere ...

IO Biotech has deployed its unique approach to modulate TGFb1 activity in the TME, and the poster details the identification and characterization of highly selective TGFb1 peptide vaccines.

Log in MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 Mar. 25, 2025 8:46 AM ETMAIA Biotechnology, Inc. (MAIA) Q4: 2025-03-21 Earnings Summary ...

Poster also to be presented on highly selective Erk1/2 inhibitor compound QUÉBEC CITY, March 28 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that ...

The second abstract accepted for poster presentation contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1. Poster Presentations ...

Poster Presentation Details Poster title: “Phase 2 Study of Telomere-Targeting Agent THIO Sequenced With Cemiplimab in Third-Line Immune Checkpoint Inhibitor–Resistant Advanced NSCLC ...

PanGIA Biotech Announces Upcoming ASCO 2025 Poster Presentation of Collaborative Research Provided by Business Wire Apr 30, 2025, 12:16:00 PM ...

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines ...

The third poster contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1. Poster Presentations ...